Gossamer Bio is trading at $10.80, up 10.59%, on October 28, 2026; no confirmed company-specific announcement explaining the gain surfaced. - The biotech sector was up 2.18%, a possible tailwind, but did not fully account for the larger share move. - The latest company-related coverage was an October 26 report that Chardan reiterated its Buy rating and $160 price target, not a new October 28 catalyst. - Broader indexes were only modestly higher, leaving the cause uncertain.